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AbsTrACT
Objective complex phenotypes captured on 
histological slides represent the biological processes 
at play in individual cancers, but the link to underlying 
molecular classification has not been clarified or 
systematised. in colorectal cancer (crc), histological 
grading is a poor predictor of disease progression, 
and consensus molecular subtypes (cMss) cannot be 
distinguished without gene expression profiling. We 
hypothesise that image analysis is a cost- effective tool 
to associate complex features of tissue organisation 
with molecular and outcome data and to resolve 
unclassifiable or heterogeneous cases. in this study, we 
present an image- based approach to predict crc cMs 
from standard h&e sections using deep learning.
Design Training and evaluation of a neural network 
were performed using a total of n=1206 tissue sections 
with comprehensive multi- omic data from three 
independent datasets (training on FOcUs trial, n=278 
patients; test on rectal cancer biopsies, graMPian 
cohort, n=144 patients; and The cancer genome atlas 
(Tcga), n=430 patients). ground truth cMs calls were 
ascertained by matching random forest and single 
sample predictions from cMs classifier.
results image- based cMs (imcMs) accurately 
classified slides in unseen datasets from Tcga 
(n=431 slides, aUc)=0.84) and rectal cancer biopsies 
(n=265 slides, aUc=0.85). imcMs spatially resolved 
intratumoural heterogeneity and provided secondary calls 
correlating with bioinformatic prediction from molecular 
data. imcMs classified samples previously unclassifiable 
by rna expression profiling, reproduced the expected 
correlations with genomic and epigenetic alterations and 
showed similar prognostic associations as transcriptomic 
cMs.
Conclusion This study shows that a prediction of rna 
expression classifiers can be made from h&e images, 
opening the door to simple, cheap and reliable biological 
stratification within routine workflows.
InTrODuCTIOn
Colorectal cancer (CRC) is a disease with heteroge-
neous molecular subtypes, variable clinical course 
and prognosis.1 An increasing understanding of 
CRC biology has led to the development of targeted 
treatments directed against key pro- oncogenic 
significance of this study
What is already known on this subject?
 ► Previous research has shown that there are four 
distinct colorectal cancer subtypes defined by 
common patterns of gene expression.
 ► Clinicians hope that these consensus molecular 
subtypes (CMSs) of colorectal cancer could 
support patient stratification for precision 
therapy.
 ► Currently, colorectal cancer subtype is 
established through RNA analysis, which is not 
widely used due to high costs and the need for 
specialist knowledge to interpret the data.
What are the new findings?
 ► Computational models can predict 
transcriptional subtypes of colorectal cancer 
from standard histology sections.
 ► Image- based CMS (imCMS) makes sequencing 
information interpretable through association 
of tile level predictions with morphology, 
molecular features and outcome data.
 ► imCMS classifies samples previously 
unclassifiable by RNA expression profiling, 
gives a novel insight into tumour heterogeneity 
and shows similar prognostic associations as 
transcriptomic CMS.
 ► imCMS classifies endoscopic biopsies and 
resection specimens of colorectal cancer 
laying the methodological basis for patient 
stratification in diverse clinical settings.
How might it impact on clinical practice in the 
foreseeable future?
 ► A prediction of RNA expression classifiers 
can be made from H&E images, opening the 
door to simple, cheap and reliable biological 
stratification within routine workflows and 
existing retrospective cohorts.
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signalling pathways, but these treatments are only effective in a 
small proportion of patients.2 Molecular stratification of patients 
with CRC is essential to form homogeneous subgroups for 
targeted treatment and prognosis.3 Next generation sequencing 
technologies enable the multi- omic profiling of malignant 
tumours but mutation and copy number data have been of 
limited impact in CRC, while more informative RNA analyses 
are more costly, difficult to standardise and require data storage 
and bioinformatics expertise.4 5 In contrast, histopathology slides 
are inexpensive to produce and principal stains such as H&E are 
firmly established in the pathology laboratory.
The application of traditional image analysis to histopathology 
facilitates the quantitative assessment of tissue architecture, 
cell distribution and cellular morphology by light microscopy 
to generate feature libraries of unprecedented resolution and 
detail.6 More recently, deep learning is being used to capture 
morphological differences with a precision that exceeds human 
performance. Coudray et al7 use this approach to detect targe-
table oncogenic driver mutations in lung cancer using deep neural 
classification networks. By combining an image- based analysis 
with molecular characterisation, it is now feasible to identify 
novel genotype–phenotype correlations. Complex multi- scale 
morphological traits as well as genomic alterations can now be 
characterised at scale and with short turnaround times. Given 
that H&E processing allows analysis of large tissue sections 
within existing clinical workflows, the discovery of morpho- 
molecular correlations holds the promise of improving patient 
stratification in clinical practice through the development of new 
image- based biomarkers.8
In CRC, it is well known that tumour morphology, growth 
pattern and architecture hold important clues to differentiating 
biological subtypes with clinical impact.9 The composition of 
the tumour microenvironment is a key component determining 
the tumour progression and therapy response.10 Tumour and 
non- tumour tissue contributes to image information on the 
histological slide and to the consensus molecular subtype (CMS) 
classification of CRC at the transcriptional level.11 The CMS 
classification distinguishes four groups of CRC with distinct 
clinical behaviour and underpinning biology. These include 
CMS1 (14%; microsatellite instability immune, favourable 
prognosis in early- stage disease, adverse prognosis in the meta-
static setting), CMS2 (37%; canonical, epithelial gene expres-
sion profile, WNT and MYC signalling activation, intermediate 
prognosis), CMS3 (13%; epithelial profile with evident meta-
bolic dysregulation, intermediate prognosis) and CMS4 (23%; 
mesenchymal, prominent transforming growth factor-β activa-
tion, poor prognosis).1 11 Samples with transitioning phenotypes 
or intratumoural heterogeneity are presently considered to be 
unclassifiable (13%). Prior studies have shown the feasibility 
of developing image- based biomarkers for molecular subtypes 
of CRC by deep learning.12 An association of specific imaging 
features with meta- gene expression profiles was described and 
preliminary data were subsequently reported indicating that 
histology slides may contain sufficient information to predict the 
CMS molecular subtypes of CRC.13
Ongoing research is investigating associations between clinical 
interventions and CMS subgrouping, and so this classification 
has the potential to guide treatment allocation in future clin-
ical practice.1 11 However, clinical implementation of the CMS 
classification has been held back by the considerable costs of 
RNA sequencing, the inability to obtain confident CMS calls 
from single samples bioinformatically, intratumoural heteroge-
neity and high levels of unclassified calls when limited mate-
rial is available.11 14 15 Here, we derive a novel image- based 
CMS (imCMS) classification from H&E- stained tissue sections 
sourced from the Medical Research Council (MRC) and Cancer 
Research UK (CRUK) Stratification in COloRecTal cancer 
(S:CORT) programme and The Cancer Genome Atlas (TCGA). 
We demonstrate the existence of distinct image phenotypes of 
CRC that reproducibly associate with CMS transcriptional clas-
sification, key oncogenic driver mutations and prognosis. Auto-
matic, high- fidelity classification of three independent clinical 
cohorts including preoperative biopsies underlines the applica-
bility of this approach to heterogeneous sample sets and relevant 
clinical settings. Our analysis provides a more localised analysis 
than is currently possible using routine RNA sequencing. Hence, 
imCMS allows us to analyse the spatial variation in the tissue, 
providing new ways of assessing tumour heterogeneity. In three 
cohorts including tissue samples from highly diverse clinical 
settings, imCMS successfully classified CRC samples that were 
previously considered to have unknown biological and clinical 
behaviour and failed transcriptional classification. imCMS clas-
sification is standardised, inexpensive and could be carried out 
in a telepathology setting on routinely available H&E sections. 
This opens up new avenues for the translation of the transcrip-
tional classification of CRC into clinical practice and has the 
potential to increase availability of molecular stratification in 
low resource settings.
MATerIAls AnD MeTHODs
study design
The study design, cohorts and aims are outlined in figure 1. 
Detailed methods for all studies are provided in the online 
supplementary materials and methods.
Patient and public involvement
This project is tackling research gaps (RGs) identified by authors 
of this study (IT, VHK) in the Bowel Cancer UK ‘Critical 
research gaps and recommendations to inform research prioriti-
sation for more effective prevention and improved outcomes in 
colorectal cancer’ research project, published in Gut in 2018.16 
Briefly, RGs in CRC were identified by a multidisciplinary panel 
of patients, clinicians and researchers (n=71) organised in eight 
working groups as described in https:// gut. bmj. com/ content/ 67/ 
1/ 179# DC1. Draft papers developed by each working group 
were evaluated by a 20- strong patient panel. A final list of RGs 
and research recommendations (RR) was endorsed by all partic-
ipants. Key RGs were identified in the pathological assessment 
of CRC (RG7). The working group highlighted the importance 
of integrating genomics, big data science and digital pathology 
methods to improve the morpho- molecular taxonomy and 
biological stratification of CRC (RR7.1, R.2, RG7.3, RG8). The 
present study aims to address these recommendations through 
the development of multiparameter algorithms for analysis of 
routine H&E slides in the pathology laboratory. Results from 
this study were communicated to the patient community through 
Bowel Cancer UK.17 18
resulTs
A deep learning framework for imCMs classification of CrC 
histology slides
The aim of this study was to develop an image analysis framework 
to associate features of tissue organisation on standard histology 
slides with molecular classification and outcome data in patients 
with CRC. Training and test cohorts were selected to represent 
relevant clinical scenarios in the management of patients with 
CRC including postoperative resection specimens (FOCUS and 
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Figure 1 Data, study design and imCMS classification framework. Three independent datasets (FOCUS, TCGA and GRAMPIAN) were used in this 
study. (A) The distribution of the samples stratified by the CMS calls in each dataset. (B) The FOCUS dataset was primarily used for learning the 
imCMS discriminative model, while the TCGA and GRAMPIAN datasets were used for testing. (C) Training of the imCMS discriminative model based 
on the domain adversarial approach. Image tiles were extracted from annotated tumour regions. Tiles from the FOCUS cohort were categorised 
by CMS class of the original slide and were used to train the model to predict the imCMS classes on unseen datasets. Tiles from the TCGA and 
GRAMPIAN cohorts were unlabelled and were used together with those from the FOCUS cohort in the cohort (domain) prediction. Domain adversarial 
training forced the cohort classifier to perform poorly, which in turn encouraged the model to learn indiscriminative features across datasets. Five 
distinct models were produced. (D) At the inference time, the ensemble of the learnt models predicts the imCMS class for each of the image tiles 
extracted from annotated tumour regions of a slide. A slide is assigned to the imCMS class with the maximum prediction score (ie, highest number of 
tiles in the slide). imCMS, image- based consensus molecular subtype; TCGA, The Cancer Genome Atlas.
TCGA) and endoscopic biopsy material (GRAMPIAN). A total 
of 1540 slides from three independent datasets were utilised 
in this study including 666 slides of resection specimens from 
362 patients in the FOCUS cohort, 468 slides of resection spec-
imens from 463 patients in the TCGA cohort and 406 slides 
from preoperative biopsies of 223 patients in the GRAMPIAN 
cohort (figure 1A). Tumour areas on each slide were annotated 
by a pathologist, and the molecular analysis was performed on 
material obtained from strict serial sections to derive the CMS 
calls (figure 1B). Clinical and molecular data are summarised in 
online supplementary table S1.
The imCMS classifier was trained against CMS calls on the 
transcriptionally classified samples of the FOCUS cohort (510 
slides, 278 patients) and tested on the TCGA (431 slides, 430 
patients) and GRAMPIAN (265 slides, 144 patients) cohorts 
(online supplementary materials and methods). With the 
assumption that each CMS class is associated with unique histo-
logical patterns localised in different regions of the tumours,14 
inception V319 deep neural networks were trained for predic-
tion of CMS calls for small overlapped image regions (tiles) of 
512×512 pixels within the annotated regions (figure 1C). The 
size distribution of annotated areas per slide and the number 
of tiles per slide is shown in online supplementary figure S1. 
The imCMS class, prediction score and spatial location for each 
tile were recorded. An overall imCMS call for each slide was 
assigned based on the majority classification of tiles (figure 1D).
evaluation of imCMs classification
We systematically compared the performance of the imCMS 
classifier across all three cohorts. For benchmarking against 
molecular data, all unclassified samples were excluded from the 
test set. Classification performance was compared using image 
tiles derived at (a) 3× and (b) 12× magnification to determine 
the effect of detail levels. In the FOCUS training cohort, a robust 
imCMS classification performance of 0.88 AUC was reached 
(table 1, online supplementary table S2, S3). imCMS classifi-
cation was then tested on the unseen TCGA and GRAMPIAN 
cohorts (table 1, online supplementary tables S2, S3). In general, 
imCMS trained at 3× provides comparable classification with 
that trained at 12× on whole tissue sections (AUC FOCUS: 0.88 
at 3× vs 0.87 at 12×, p value=0.084; TCGA: 0.81 at 3× vs 
0.8 at 12×, p value=0.058; GRAMPIAN: 0.82 at 3× vs 0.83 at 
12×, p value=0.427, DeLong’s test20).
CRC resection specimens (FOCUS, TCGA) and biopsies 
(GRAMPIAN) were used for algorithm training and testing. 
Samples from these cohorts have been prepared in separate 
institutions using different protocols and exhibit the expected 
range of morphological differences due to discrete preprocessing 
and preparation steps. The combination of these three specific 
cohorts captures sample variability as commonly encountered 
in pathology practice and provides an excellent opportunity 
to evaluate the generalisability of imCMS. Domain adver-
sarial learning, a machine learning method that promotes the 
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Table 1 Area under the curve with 95% CIs achieved by the imCMS classifier
CMs class
FOCus
n slides=510
n patients=278
TCGA
n slides=431
n patients=430
GrAMPIAn
n slides=265
n patients=144
3× 12× 3× 12× 3× 12×
CMS1 0.83 (0.78 to 0.87) 0.85 (0.81 to 0.89) 0.82 (0.77 to 0.89) 0.82 (0.76 to 0.88) 0.76 (0.65 to 0.85) 0.82 (0.75 to 0.92)
CMS2 0.88 (0.85 to 0.92) 0.86 (0.83 to 0.91) 0.84 (0.81 to 0.88) 0.82 (0.78 to 0.86) 0.78 (0.72 to 0.83) 0.75 (0.71 to 0.82)
CMS3 0.93 (0.91 to 0.97) 0.9 (0.85 to 0.94) 0.75 (0.67 to 0.83) 0.74 (0.68 to 0.81) 0.81 (0.75 to 0.9) 0.79 (0.73 to 0.88)
CMS4 0.87 (0.83 to 0.9) 0.85 (0.82 to 0.89) 0.84 (0.79 to 0.88) 0.82 (0.77 to 0.87) 0.94 (0.9 to 0.98) 0.94 (0.91 to 0.99)
Macro- average 0.88 (0.86 to 0.9) 0.87 (0.84 to 0.89) 0.81 (0.78 to 0.84) 0.8 (0.77 to 0.83) 0.82 (0.78 to 0.87) 0.83 (0.79 to 0.86)
CMS, consensus molecular subtype; imCMS, image- based consensus molecular subtype; TCGA, The Cancer Genome Atlas.
Table 2 Area under the curve with 95% CIs achieved by the imCMS classifier trained by domain adversarial training
(A) FOCus
CMs
3× (n slides=510, n patients=278)
Model 1 Model 2 Model 3 Model 4 Model 5 Overall
CMS1 0.85 (0.77 to 0.96) 0.78 (0.64 to 0.93) 0.95 (0.91 to 1) 0.89 (0.82 to 0.97) 0.83 (0.72 to 0.97) 0.86 (0.81 to 0.92)
CMS2 0.9 (0.85 to 0.97) 0.96 (0.93 to 1) 0.93 (0.89 to 0.98) 0.9 (0.84 to 0.97) 0.87 (0.8 to 0.94) 0.91 (0.88 to 0.93)
CMS3 0.89 (0.81 to 1.02) 0.98 (0.97 to 1.01) 0.81 (0.67 to 1.01) 0.96 (0.92 to 0.99) 0.91 (0.86 to 0.99) 0.92 (0.88 to 0.98)
CMS4 0.89 (0.84 to 0.99) 0.9 (0.83 to 0.98) 0.88 (0.82 to 0.97) 0.89 (0.81 to 0.99) 0.91 (0.86 to 0.97) 0.89 (0.87 to 0.93)
Macro- average 0.88 (0.83 to 0.95) 0.9 (0.86 to 0.95) 0.89 (0.83 to 0.95) 0.91 (0.87 to 0.94) 0.88 (0.84 to 0.93) 0.9 (0.87 to 0.91)
(b) TCGA
CMs
3× (n slides=431, n patients=430)
Model 1 Model 2 Model 3 Model 4 Model 5 ensemble
CMS1 0.84 (0.79 to 0.91) 0.87 (0.83 to 0.92) 0.84 (0.78 to 0.91) 0.82 (0.77 to 0.89) 0.82 (0.75 to 0.88) 0.85 (0.8 to 0.9)
CMS2 0.88 (0.85 to 0.91) 0.87 (0.83 to 0.91) 0.87 (0.84 to 0.91) 0.83 (0.79 to 0.88) 0.83 (0.8 to 0.87) 0.89 (0.85 to 0.92)
CMS3 0.82 (0.76 to 0.88) 0.76 (0.7 to 0.82) 0.76 (0.7 to 0.83) 0.76 (0.67 to 0.82) 0.73 (0.66 to 0.81) 0.78 (0.71 to 0.85)
CMS4 0.84 (0.79 to 0.87) 0.84 (0.8 to 0.88) 0.8 (0.76 to 0.85) 0.81 (0.77 to 0.86) 0.8 (0.75 to 0.85) 0.83 (0.78 to 0.87)
Macro- average 0.84 (0.81 to 0.87) 0.83 (0.8 to 0.86) 0.82 (0.78 to 0.85) 0.8 (0.77 to 0.84) 0.79 (0.76 to 0.83) 0.84 (0.8 to 0.87)
(C) GrAMPIAn
CMs
12× (n slides=265, n patients=144)
Model 1 Model 2 Model 3 Model 4 Model 5 ensemble
CMS1 0.79 (0.71 to 0.87) 0.63 (0.51 to 0.74) 0.78 (0.66 to 0.87) 0.84 (0.77 to 0.93) 0.87 (0.82 to 0.95) 0.87 (0.81 to 0.94)
CMS2 0.83 (0.78 to 0.89) 0.73 (0.67 to 0.78) 0.73 (0.67 to 0.8) 0.75 (0.68 to 0.81) 0.77 (0.71 to 0.83) 0.79 (0.74 to 0.84)
CMS3 0.84 (0.78 to 0.89) 0.73 (0.65 to 0.81) 0.76 (0.68 to 0.83) 0.77 (0.72 to 0.83) 0.8 (0.74 to 0.87) 0.8 (0.75 to 0.86)
CMS4 0.92 (0.88 to 0.96) 0.84 (0.78 to 0.91) 0.87 (0.81 to 0.95) 0.92 (0.88 to 0.98) 0.94 (0.9 to 0.98) 0.93 (0.89 to 0.98)
Macro- average 0.84 (0.82 to 0.88) 0.73 (0.69 to 0.79) 0.78 (0.75 to 0.82) 0.82 (0.78 to 0.86) 0.85 (0.81 to 0.88) 0.85 (0.82 to 0.89)
CMS, consensus molecular subtype ; TCGA, The Cancer Genome Atlas.
emergence of features that are discriminative for imCMS clas-
sification and indiscriminate of preanalytical variation between 
resection specimens,21 was used during model training. We lever-
aged 30% and 20% of the TCGA and GRAMPIAN cohorts in 
the domain adversarial training to discourage the learning of 
cohort- dependent features
(online supplementary materials and methods, online supple-
mentary table S4); we further propose an adaptation of the deep 
learning model for colorectal biopsy samples. It should be noted 
that rectal biopsies have inherent biological differences with a 
lower frequency of CMS1 cases and a different representation of 
microenvironment features in biopsy samples. This resulted in very 
few biopsy samples classified as imCMS1 based on the majority 
vote rule (online supplementary table S5). To find the optimal 
cut- off for making an imCMS call, we used a small proportion of 
samples in the GRAMPIAN cohort to train a random forest (RF) 
classifier to make a final imCMS call based on the prediction 
score from the imCMS classifier (online supplementary materials 
and methods, online supplementary tables S5- S6). Although the 
domain adversarial training used parts of the TCGA and GRAM-
PIAN cohorts in the training, the improvement in the classifi-
cation performance was consistent in both training and unseen 
parts of the TCGA and GRAMPIAN cohorts, alleviating the 
concern of overfitting (online supplementary table S7). Domain 
adversarial training improved classification accuracy of the final 
model to 0.9 AUC (70% average accuracy) in FOCUS (training), 
0.84 AUC (64% average accuracy) in TCGA (test) and 0.85 AUC 
(72% average accuracy) in GRAMPIAN (test) (figure 2A, online 
supplementary figure S2; table 2, online supplementary table 
S8). The results presented hereafter are based on the imCMS 
classifier optimised by domain adversarial training. The corre-
spondence of the CMS and imCMS classification calls for each 
case is shown in figure 2B. Next, we evaluated the consistency 
of the classification results on pairs of slides obtained from the 
same patients in the FOCUS and GRAMPIAN datasets. Two 
H&E slides were generated at different depth levels of each 
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Figure 2 Image- based consensus molecular subtype (imCMS) classification. (A) Receiver operating curves of the imCMS classifier, optimised 
by the domain adversarial approach, on the FOCUS (n slides=510, 3×), TCGA (n slides=431, 3×) and GRAMPIAN cohorts (n slides=265, 12×). 
(B) Correspondences between CMS and imCMS classes in different datasets. All samples labelled as unclassified by RNA- based CMS calls were 
reclassified by imCMS. (C) Examples of image tiles with high prediction confidence for each imCMS class in FOCUS. Histological patterns associated 
with imCMS1 are mucin and lymphocytic infiltration. In imCMS2, evident cribriform growth patterns and comedo- like necrosis are observed, while 
imCMS3 is characterised by ectatic, mucin- filled glandular structures in combination with a minor component showing papillary and cribriform 
morphology. imCMS4 is predominantly associated with infiltrative CRC growth pattern, a prominent desmoplastic stromal reaction and frequent 
presence of single cell invasion (tumour budding). Scale bar ~1 mm. (D) Molecular associations of the CMS classified samples (black) and the CMS 
unclassified samples that have been classified by imCMS (grey). The molecular profiles of reclassified samples are largely consistent with those of 
the classified CMS samples. Statistically significant differences (p<0.05) are marked with a red asterisk. AUC, area under the curve; TCGA, The Cancer 
Genome Atlas.
tissue block with at least four additional sections cut between for 
RNA extraction (online supplementary figure S3A). Since tissue 
features at different tissue levels are closely related, a robust clas-
sifier would be expected to achieve similar classification results. 
Indeed, imCMS classification scores were consistent between the 
slide pairs across different CMS classes (online supplementary 
figure S3B, online supplementary table S9).
Histological patterns associated with imCMs status
To understand which specific morphological patterns associate 
with imCMS, we extracted and visually reviewed tiles with the 
highest prediction confidence for each imCMS subtype. The 
large- scale histology patterns corresponded well with the biolog-
ical characteristics of the CMS1 and CMS4 classes as predicted 
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from the molecular assay11: mucinous differentiation and 
lymphocytic infiltration were associated with imCMS1, and a 
prominent desmoplastic stromal reaction with imCMS4. imCMS 
further allowed to visualise and systematically investigate tile 
level predictions for imCMS2 and imCMS3 with specific histo-
logical patterns. Image tiles associated with high- confidence calls 
of imCMS2 and imCMS3 showed a predominantly glandular 
differentiation (figure 2C, online supplementary figure 4A). In 
imCMS2, cribriform growth patterns and comedo- like necrosis 
were observed, while imCMS3 was characterised by ectatic, 
mucin- filled glandular structures in combination with a minor 
component showing papillary and cribriform morphology. 
Detailed visualisation of the image representations at the pixel- 
level22 corroborated the cellular and tissue components that 
weigh in on imCMS at high resolution (online supplementary 
figure S4B).
imCMs classification of molecularly unclassified CMs samples
Failure of the transcriptional CMS classification might represent 
a transition phenotype, intratumoural heterogeneity or might 
represent technical failure to classify.11 We therefore tested the 
performance of imCMS in samples categorised as unclassifiable 
by transcriptomic CMS (figure 2B). Reclassification is under-
lined by direct comparison of the key molecular profiles between 
classified samples and the imCMS reclassified samples. No major 
differences between these two groups in the majority of the traits 
were found (figure 2D, online supplementary figure S5, online 
supplementary table S10).
spatial variation of imCMs class labels
CRC tumours exhibit intratumoural variability in transcriptional 
features leading to a bias in transcriptional CMS calls introduced 
by the regions sampled for molecular analysis.14 imCMS captures 
this intrinsic variation in separate predictions for each image tile 
and provides a novel approach to investigate the intratumoural 
transcriptional heterogeneity of CRC (figure 3A, online supple-
mentary figure S6A- D). We show that the distribution of the 
predicted imCMS labels is not random and that the morpho-
logical patterns associated with imCMS labels are consistent 
across cohorts (online supplementary materials and methods). 
We investigated if imCMS heterogeneity was associated with 
that of the molecular classification. Comparison of the imCMS 
versus CMS prediction scores revealed a high level of agreement 
between both classification schemes in the majority of the slides 
(figure 3B, online supplementary figure S7A). We next derived 
secondary CMS calls from the molecular data (figure 3C, online 
supplementary materials and methods) and further investigated 
the similarity between the corresponding CMS and imCMS 
prediction scores in groups stratified by primary and secondary 
CMS calls. Based on the cosine similarity measure, the concor-
dance of the two prediction scores was significantly better than 
chance in a majority of the stratified groups (figure 3D, online 
supplementary figures S7B, S9, online supplementary materials 
and methods).
Prognostic associations by imCMs status
We performed univariate Cox proportional hazard analysis to 
assess the prognostic associations of the imCMS classification 
compared with its molecular counterpart. The trend of patient 
survival outcomes stratified by imCMS was largely in agreement 
with those of the transcriptional classification (figure 4, online 
supplementary table S11) and imCMS survival predictions were 
concordant when the input slides were replaced by sections cut at 
deeper tissue levels in FOCUS and GRAMPIAN (online supple-
mentary table S11, online supplementary figure S8). The prog-
nostic association of the imCMS classification was maintained 
in multivariable analysis including TNM stage, age and gender, 
indicating strong potential to stratify risk beyond pathological 
staging (online supplementary table S11). In TCGA, a tendency 
towards worse overall survival was identified for cases classified 
as imCMS1 compared with molecular CMS in univariate anal-
ysis (imCMS HR=1.88, p value=0.027 vs CMS HR=1.35, p 
value=0.308). The same trend was captured in the multivariable 
analysis but was not statistically significant (imCMS HR=1.78, 
p=0.007 vs CMS HR=1.41, p=0.285). This discrepancy in the 
TCGA cohort may reflect the ability of the classifier to iden-
tify inherently poor prognosis CMS1 cases due to training on 
a cohort of metastatic CRC (FOCUS) and requires additional 
investigation in subsequent studies. TCGA cases classified as 
CMS4 showed a worse prognosis in univariate progression- free 
interval analysis (HR=1.68, p=0.028) while CMS1 associated 
with adverse outcome in multivariable analysis. Similar prog-
nostic trends were reproduced by imCMS but did not reach 
statistical significance. In GRAMPIAN, both CMS and imCMS 
produced similar survival trends in both univariate and multi-
variate relapse- free survival analyses. Nevertheless, imCMS4 
exhibits a stronger trend towards worse prognosis in the multi-
variate analysis compared with CMS4 (imCMS HR>6.63, p 
value<0.05 vs CMS HR=5.99, p value=0.061).
DIsCussIOn
H&E slides are generated as part of the standard work- up of 
any CRC treated by surgical resection. In the assessment of this 
histologic material, pathologists are presently limited to a strictly 
defined set of morphologic and anatomic criteria.23 24 This infor-
mation supports the definition of broad prognostic risk groups 
but has no predictive value.24 The integration of genomic tech-
nologies in the clinical care of patients with CRC has immense 
potential to drive personalised treatment and is now widely 
implemented for panel- based DNA analysis. While this is of great 
value in some tumour types such as non- small cell lung cancer, 
in CRC and many other tumour types the impact is relatively 
minor. Gene expression data provide information regarding the 
behaviour of epithelial, stromal and immune compartments of 
the tumour, which is more informative especially in CRC as the 
basis for the CMS subtyping, but requires substantial financial, 
personnel and infrastructure resources.1 Combining morpho-
logical and molecular pathology is a promising approach to 
extend the amount of clinically relevant information that can 
be extracted from standard histologic slides.8 25 In this study, we 
leverage advanced machine learning for the development of an 
image- based taxonomy of CRC that was previously inaccessible 
to human interpretation.
We trained and tested the imCMS approach towards consensus 
molecular subtyping of CRC on three independent and well- 
characterised patient cohorts with availability of digital slides 
and transcriptional information from the MRC CRUK S:CORT 
consortium and TCGA. We specifically focused on relevant clin-
ical scenarios in the management of patients with CRC and inves-
tigated the imCMS classification of both preoperative biopsies 
and resection specimens. Our analysis demonstrates the feasi-
bility of imCMS classification of both primary colon and rectal 
resection specimens in the FOCUS and TCGA cohorts. imCMS 
calls closely matched transcriptional classification for survival 
stratification, underlining the potential of imCMS to aid pathol-
ogists in the identification of aggressive disease for intensified 
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Figure 3 Intratumoural heterogeneity of the imCMS molecular subtypes. (A) Visualisation of the regional classification of the imCMS classifier. 
imCMS classification of a tumour sample can exhibit uniform results (left) or a degree of variation in the predicted imCMS class and the level of 
confidence (right). The colour overlay indicates the imCMS classes and the opacity reflects the classification confidence. (B) Heterogeneity of the CMS 
and imCMS classification scores. Each bar represents classification scores of a sample, and samples are sorted by the entropy of the prediction scores 
from the molecular- based random forest CMS classifier. (C) Heterogeneity of the CMS classification. A secondary CMS call was derived by relaxing 
the classification threshold of the random forest CMS classifier.11 (D) Cosine similarity between the imCMS and CMS prediction scores, stratified by 
the primary and secondary CMS calls. The levels of similarity were compared against those produced by a random classifier. Statistical analysis was 
performed using Wilcoxon rank- sum test, adjusted for the false discovery rate. P value <0.05 was considered statistically significant. n indicates the 
number of patients. Note that two diagnostic slides (serial sections) were available for the majority of cases in the FOCUS and GRAMPIAN cohorts. In 
cases where two slides were available, the analyses for each slide were performed separately. Panels (B) and (D) report the results for the first slide. 
The matched results for the second slide are provided in online supplementary figure S10. imCMS predictions represent the calls made by the domain 
adversarially trained imCMS classifier. imCMS, image- based consensus molecular subtype; TCGA, The Cancer Genome Atlas.
follow- up and chemotherapy trials.1 In advanced disease, the 
development of molecular stratifiers for the prediction of treat-
ment response is of critical importance to balance care and over-
treatment. No clinically approved tests are currently available to 
predict chemotherapy response in metastatic CRC and beneficial 
effects are set- off by considerable toxicity.26 27 Transcriptional 
classification of CRC has shown promise to stratify survival 
outcomes and response to treatment in retrospective analyses but 
requires further validation.26 28 29 imCMS represents a readily 
translatable and cost- effective approach for further investigation 
of treatment outcomes in existing retrospective cohorts with 
potential to inform future clinical trials.
Small biopsy fragments have previously proven difficult to 
analyse using genomic technologies due to the limited amount 
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Figure 4 Prognostic associations of the image- based consensus molecular subtypes (imCMSs). Overall survival (OS) outcomes of the FOCUS 
cohort (n=278 patients, (A)) and TCGA cohort (n=395 patients, (B)), progression- free interval (PFI) outcome of the TCGA cohort (n=395, (C)) and 
relapse- free survival (RFS) outcome (n=83, (D)) as stratified by the transcriptional- based CMS classification and imCMS classification produced by the 
domain adversarially trained imCMS classifier. Kaplan–Meier estimator was used to estimate the survival probability, and pairwise log- rank test and 
univariate Cox proportional hazards regression were performed between CMS groups and imCMS groups. HRs and 95% CI for pairwise comparisons 
were reported. Test results with p value<0.05 were considered statistically significant. TCGA, The Cancer Genome Atlas.
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of tissue available and pathologist assessment is usually restricted 
to the diagnosis of cancer, a select panel of immunohistochem-
ical studies and a limited assessment of additional prognostic 
features.27 30 We found that imCMS could be efficiently adapted 
for morpho- molecular classification of rectal cancer biopsy frag-
ments at high magnification. Further study where the model is 
trained on biopsy samples and evaluated on independent biopsy 
cohorts is required. Clinically approved assays that are predic-
tive of therapeutic response from biopsy material are presently 
lacking, with up to 25% of patients with rectal cancer gaining 
no benefit from current radiotherapy and chemotherapy proto-
cols.29 As a stemlike (CMS4) transcriptional profile of CRC 
has been linked to poor prognosis and therapeutic resistance, 
imCMS could allow for more effective stratification of patients 
for prospective studies in primary surgery or neoadjuvant 
treatment.31
The robustness of image analysis algorithms is a well- 
recognised problem in the setting of limited training sets and 
poorly annotated reference data. We addressed the problem of 
sample diversity by training the imCMS classifier on histological 
samples sourced from multiple institutions (n=59) participating 
in the FOCUS trial. We also included endoscopic biopsies and 
surgical resections as two diverse examples of CRC tissue spec-
imens with different preprocessing procedures. Biopsy tissue 
undergoes relevant compression stress during capture by endo-
scopic forceps leading to architectural distortion and variable 
alteration of cellular morphology. We show that imCMS classi-
fication is relatively stable across these settings. Domain adver-
sarial training was used to further minimise learning features 
that are attributed to a specific cohort.21 Indeed, an ensemble of 
multiple models, analogous to consensus of experts’ opinions, 
reduces the bias of individual predictions.21 Our study underlines 
that convolutional neural networks excel in their ability to learn 
relationships of tissue compartments as a whole and to identify 
relevant patterns with clear morphological interpretability. The 
resulting feature space represented both tumour- intrinsic and 
microenvironment- related signals, which are intimately linked 
to CRC phenotypes with distinct biological characteristics and 
disease outcomes. Indeed, imCMS highlighted the well- known 
morpho- molecular associations with inflammatory infiltrates 
(imCMS1) and a prominent stromal reaction (imCMS4) but also 
identified novel morphological features in association with high- 
confidence calls of imCMS2 and imCMS3. Despite these prom-
ising results, potential overfitting of the computational model 
to the training cohort is a limitation of the current study, and 
results need to be interpreted in the context of the current stage 
of research development.
Transcriptomic CMS was released as the most robust molec-
ular classification in CRC and the basis for clinical stratifi-
cation and targeted intervention.1 11 However, some key 
issues hamper clinical implementation of CMS such as the 
inability to obtain reliable calls from single samples. Two 
methods to call CMS were released by the original authors 
based on RF and single sample prediction.1 11 RF classifi-
cation is cohort- dependent and requires a high minimum 
number of samples, while calls on single samples are often 
of limited quality leading to underutilisation. Some samples 
do not show enough evidence to make calls by either method 
leading to a substantial number of cases left as unclassified. 
Inconsistent classification calls could also be an expression 
of intratumoural heterogeneity or representative of a transi-
tion phenotype, which is of considerable biological interest.1 
imCMS is able to overcome all these problems. First, imCMS 
calls are intrinsically generated for single samples. Second, 
imCMS classification visualises heterogeneity through tile- 
based calls with a cell size of 512×512 pixels, leading to 
quantitative prediction scores while retaining the value of 
an image to support understanding at a pathomorphological 
level. Importantly, all CMS unclassified samples were reclas-
sified by imCMS, with their molecular characteristics closely 
resembling those classified by sequencing methods. Our results 
suggest that imCMS performs reliably in samples categorised 
as unclassified by transcriptional profiling. Nonetheless, this 
should not be interpreted that the stratification of unclassi-
fied samples into molecular subgroups is considered correct. 
Rather, imCMS provides a tile- based overlay of CMS subtypes 
across a single section, thereby providing rich information 
about tissue heterogeneity and spatial context readily acces-
sible to the reporting pathologist. imCMS is a versatile tool to 
address deficiencies in transcriptional profiling that may arise 
due to low amounts or quality of RNA, an expected problem 
in clinical formalin- fixed paraffin- embedded blocks. Impor-
tantly, it offers a possible alternative solution when there is 
an inability to confidently call CMS in single samples from 
transcriptomic data.
Tumour heterogeneity introduces important challenges 
in designing optimal treatment strategies for patients with 
cancer.14 30 To investigate sample heterogeneity, we bioinfor-
matically derived secondary CMS calls from all samples and 
investigated the similarity of the CMS and imCMS predic-
tion scores for primary and secondary calls. imCMS captured 
secondary calls with high accuracy based on a cosine similarity 
measure between transcriptional and image- based classification. 
Hallmark of imCMS is the ability to predict a class label for 
a given image tile and hence the ability to estimate a distribu-
tion of labels in a given tumour area. We provide evidence that 
the distribution of imCMS labels is not random, it is consistent 
across the different cohorts, and the reinterpretation of RNA 
expression is in line with local imCMS label predictions. Further 
investigation of local tumour heterogeneity using methods such 
as spatial transcriptomics is warranted.
Prospective validation of imCMS in independent studies will 
be critical to clinical translation. A first application will be its 
use as a tool to call CMS in large clinical trial cohorts in whom 
funding for gene expression profiling is not available. This will 
build the evidence base to show whether or not imCMS can be 
used as a predictive biomarker for treatment response or patient 
enrichment for certain research studies. We hypothesise that the 
general principle can be applied not only to other cancer types 
but also to other diseases. It will therefore lay the foundation 
of a more systematic integration of image- based morphological 
analysis and molecular stratification.
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